Vera Therapeutics (VERA) News Today $28.41 -1.52 (-5.08%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$28.26 -0.15 (-0.51%) As of 03/3/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Q1 Earnings Forecast for Vera Therapeutics Issued By WedbushMarch 4 at 1:17 AM | americanbankingnews.comQ1 EPS Estimates for Vera Therapeutics Boosted by WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush raised their Q1 2025 EPS estimates for shares of Vera Therapeutics in a research note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico now expects that the company will post earningMarch 3 at 1:16 AM | marketbeat.comWhat is Wedbush's Forecast for VERA FY2029 Earnings?March 2 at 2:51 AM | americanbankingnews.comFY2029 Earnings Forecast for VERA Issued By WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at Wedbush issued their FY2029 EPS estimates for shares of Vera Therapeutics in a note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico forecasts that the company will earn $2.16 per share for the yMarch 1 at 9:24 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $61.00 at GuggenheimMarch 1 at 2:29 AM | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Trading Up 7.6% Following Strong EarningsVera Therapeutics (NASDAQ:VERA) Trading 7.6% Higher After Better-Than-Expected EarningsFebruary 28, 2025 | marketbeat.comGuggenheim Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceGuggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comVera Therapeutics price target raised to $61 from $59 at GuggenheimFebruary 27, 2025 | markets.businessinsider.comVera Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)February 27, 2025 | markets.businessinsider.comDelveInsight Business Research, LLP: The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsightFebruary 26, 2025 | finanznachrichten.deThe Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsightFebruary 26, 2025 | finance.yahoo.comVera Therapeutics (NASDAQ:VERA) Announces Earnings ResultsVera Therapeutics (NASDAQ:VERA - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11.February 26, 2025 | marketbeat.comVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | globenewswire.comVera Therapeutics selloff a buying opportunity, says Evercore ISIFebruary 18, 2025 | markets.businessinsider.comVera Therapeutics pullback a buying opportunity, says Cantor FitzgeraldFebruary 18, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Vera Therapeutics (VERA)February 17, 2025 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - What's Next?Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month Low - Here's WhyFebruary 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Buy" from BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation andFebruary 15, 2025 | marketbeat.comVera Therapeutics stock hits 52-week low at $31.64February 14, 2025 | msn.comWolfe Research Upgrades Vera Therapeutics (NASDAQ:VERA) to "Strong-Buy"Wolfe Research raised shares of Vera Therapeutics to a "strong-buy" rating in a research report on Monday.February 5, 2025 | marketbeat.comJennison Associates LLC Has $34.42 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Jennison Associates LLC increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 813,861 shares of the company's stock after buying an adFebruary 5, 2025 | marketbeat.comVera Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 4, 2025 | markets.businessinsider.comWolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform RecommendationFebruary 4, 2025 | msn.comWolfe Research Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $49.00 price target for the company.February 4, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading Up 4.9% - Still a Buy?Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9% - Here's What HappenedJanuary 29, 2025 | marketbeat.comSG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)SG Americas Securities LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 116.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,270 shares of the company's stock after purchasing an adJanuary 29, 2025 | marketbeat.comVera started at buy by Goldman Sachs, atacicept potential citedJanuary 28, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What HappenedVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Time to Buy?January 28, 2025 | marketbeat.comThe Goldman Sachs Group Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)The Goldman Sachs Group began coverage on Vera Therapeutics in a report on Tuesday. They set a "buy" rating and a $58.00 price objective for the company.January 28, 2025 | marketbeat.comVera Therapeutics initiated with a Buy at Goldman SachsJanuary 27, 2025 | markets.businessinsider.comBiotech Market Forecast: Top Trends for Biotech in 2025January 24, 2025 | msn.comVera Therapeutics: Promising Clinical Progress and Strategic Positioning Drive Buy RatingJanuary 24, 2025 | markets.businessinsider.comBrokers Issue Forecasts for VERA FY2025 EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. StavropoulosJanuary 23, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Vera Therapeutics (VERA)January 22, 2025 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have received a consensus rating of "Buy" from the nine research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy ratingJanuary 21, 2025 | marketbeat.comVera Therapeutics: Strategic Licensing and Promising Clinical Data Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comEvercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)January 14, 2025 | markets.businessinsider.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 14, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider SellingJanuary 13, 2025 | marketbeat.comVera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL InhibitorJanuary 13, 2025 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $730,450.00 in StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.January 10, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell?Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell?January 10, 2025 | marketbeat.comVera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comGeode Capital Management LLC Buys 20,223 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 2.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,004,665 shares of the company's stock after acquiringDecember 24, 2024 | marketbeat.comPromising Developments in VYNE Therapeutics’ VYN202 Support Buy RatingDecember 23, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLCBarclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,395 shares of the company's stock after buying an additioDecember 23, 2024 | marketbeat.comVera Therapeutics: Strong Data In IgAN, But We May Be Too LateDecember 22, 2024 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.December 20, 2024 | marketbeat.comWellington Management Group LLP Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Wellington Management Group LLP lowered its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,071 shares of the compaDecember 20, 2024 | marketbeat.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.870.70▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼205▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BridgeBio Pharma News Today Legend Biotech News Today Axsome Therapeutics News Today Blueprint Medicines News Today Cytokinetics News Today Nuvalent News Today Elanco Animal Health News Today Lantheus News Today Krystal Biotech News Today Verona Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
